Matinas Biopharma Holdings Inc (MTNB)

[vdt]

Matinas BioPharma MTNB is gonna be a rocket, with good news!

--Positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis.

--The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

--In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first ten weeks of antifungal treatment.

--Enrollment in Cohort 3 of EnACT has commenced and is expected to complete by the end of 2021. Cohort 3 is the safety lead-in for Cohort 4, an all-oral MAT2203 treatment regimen.